-
Product Insights
Likelihood of Approval Analysis for Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that the drugs in Secondary Progressive Multiple Sclerosis (SPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secondary Progressive Multiple Sclerosis (SPMS) Overview Secondary progressive multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-101 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewSecondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it...
-
Product Insights
NewCX3C Chemokine Receptor 1 – Drugs In Development, 2024
The CX3C Chemokine Receptor 1 pipeline drugs market research report outlays comprehensive information on the CX3C Chemokine Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Oncology, and Immunology which include indications of Myocardial Infarction, Atherosclerosis, Alzheimer's Disease, Secondary Progressive Multiple Sclerosis (SPMS), Ovarian Cancer, Chronic Lymphocytic Leukemia (CLL), and Inflammation. It...
-
Product Insights
NewIntegrin Alpha 4 – Drugs In Development, 2024
The Integrin Alpha 4 pipeline drugs market research report outlays comprehensive information on the Integrin Alpha 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Gastrointestinal, Immunology, Central Nervous System, and Musculoskeletal Disorders which include indications of Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Immunology, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive...
-
Product Insights
NewDihydroorotate Dehydrogenase – Drugs In Development, 2024
The Dihydroorotate Dehydrogenase pipeline drugs market research report outlays comprehensive information on the Dihydroorotate Dehydrogenase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Infectious Disease, and Ophthalmology which include indications of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Coronavirus Disease 2019...
-
Product Insights
NewC-X-3-C Motif Chemokine Receptor – Drugs In Development, 2024
The C-X-3-C Motif Chemokine Receptor pipeline drugs market research report outlays comprehensive information on the C-X-3-C Motif Chemokine Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Oncology, and Immunology which include indications of Myocardial Infarction, Atherosclerosis, Alzheimer's Disease, Secondary Progressive Multiple Sclerosis (SPMS), Ovarian Cancer, Chronic Lymphocytic Leukemia (CLL), and Inflammation. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Primary Sjogren’s Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Primary Sjogren's Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Primary Sjogren's Syndrome Drug Details: Frexalimab (INX-021) is...